|
|
| | MT-1207 Basic information |
| Product Name: | MT-1207 | | Synonyms: | MT-1207;1H-Benzotriazole, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, hydrochloride (1:1) | | CAS: | 1610794-70-1 | | MF: | C21H24N6S.ClH | | MW: | 428.98 | | EINECS: | | | Product Categories: | | | Mol File: | 1610794-70-1.mol |  |
| | MT-1207 Chemical Properties |
| solubility | DMSO: Slightly soluble: 0.1-1 mg/ml | | form | Solid | | color | White to off-white |
| | MT-1207 Usage And Synthesis |
| Uses | MT-1207 is an orally active and selective adrenergic α1 and 5-HT2A receptor antagonist. MT-1207 shows IC50<0.1 nM, 0.15 nM, 1.40 nM and 0.27 nM for α1A, α1B, α1D and 5-HT2A, respectively. MT-1207 achieves an effective blood pressure (BP) reduction in the 2K2C rat model without damaging renal function. MT-1207 is a potent multitarget inhibitor with the potential for vasodilatation research[1]. | | IC 50 | α1A-adrenergic receptor: 0.1 nM (IC50); α1B-adrenergic receptor: 0.15 nM (IC50); α1B-adrenergic receptor: 1.40 nM (Ki); α1D-adrenergic receptor: 0.086 nM (IC50); α1D-adrenergic receptor: 0.69 nM (Ki); 5-HT2A Receptor: 0.27 nM (IC50); 5-HT2A Receptor: 0.079 nM (Ki) | | References | [1] Peng Wang, et al. Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension. J Med Chem. 2024 Jul 5. DOI:10.1021/acs.jmedchem.4c00626
[2] TIAN-YING XU. Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent[J]. Acta Pharmacologica Sinica, 2021, 42 6: 885-897. DOI: 10.1038/s41401-021-00636-1 |
| | MT-1207 Preparation Products And Raw materials |
|